Should you buy Novavax stock now?
No, the technical signal for Novavax is currently SELL. Novavax trades at $7.67 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.411 with rising momentum (signal: -0.421); RSI is at 40.3 (neutral zone); the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $14.11 points to 84.0% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Novavax stock?
The average analyst price target for Novavax is $14.11. The current price is $7.67, which gives an upside of 84.0%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $12.70 and $15.52.
Is Novavax a dividend stock?
No, Novavax does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Novavax stock?
Novavax is rated as a stock with high risk. the annual standard deviation is 67.3%, which classifies the stock as high risk.
Is Novavax overvalued?
No, Novavax is considered undervalued based on the analyst price target (84.0% upside). Novavax has the following valuation ratios: a P/S ratio of 2.1, a P/B ratio of 33.2. The analyst price target suggests that the stock is undervalued by 84.0%.
Is Novavax overbought?
No, Novavax is not overbought. RSI is at 40.3 (neutral zone). The technical indicators show: RSI is at 40.3 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 4.0% below the 20-day average (short-term downtrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Novavax earnings report?
Novavax reports earnings TODAY, August 6, 2026! The stock currently trades at $7.67. Watch how the price reacts after the release.
Is Novavax shorted?
Yes, Novavax is shorted with 26.8% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying Novavax stock?
No, insiders are not buying Novavax shares – they are net sellers. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 8,050,355 $ sold. Active sellers include Kelly James Patrick, O'Hara Elaine, Jacobs John C and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Novavax a good stock?
Based on our total score, Novavax is rated as a poor stock with a total score of 20 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 16/100, Quality: 18/100, Momentum: 25/100. In addition: analysts see 84.0% upside to the price target; technical signal: Strong Sell. Whether Novavax is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Novavax stock?
The outlook for Novavax based on current data: the average analyst price target is $14.11 (+84.0%); the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on 8/6/2026, which can move the price. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Novavax stock falling?
Novavax is falling right now. The technical indicators show: the price is 4.0% below the 20-day average; short interest is 26.8% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Novavax go?
The average analyst price target for Novavax is $14.11, which corresponds to a potential gain of 84.0% from the current price of $7.67. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Novavax fall?
We lack enough history to give a specific floor for Novavax. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Novavax do?
Novavax er et biotekfirma, der udvikler vacciner mod alvorlige infektionssygdomme. De tjener penge ved at forske i, udvikle og sælge disse vacciner. Novavax er især kendt for deres COVID-19 vaccine, NVX-CoV2373, som de har kørt igennem flere store forsøg.
Blandt deres andre v... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Novavax as an investment.
Did Novavax raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Novavax. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Novavax making money or losing money?
No, Novavax is currently not making money — the company is losing money with a negative profit margin of -14.7%, a noticeable loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Novavax go bankrupt?
The bankruptcy risk of Novavax is rated as elevated. Altman Z2 (a model for assessing financial distress) is -11.65 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 3 — which is weak. Debt relative to equity is 1,000% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Novavax have a lot of debt?
Yes, Novavax has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 1,000%. For the sundhed sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Novavax service its debt? Could struggle to service its debt — the interest coverage ratio (how many times earnings can cover interest payments) is -0.7x, and net debt equals 1.1 years of earnings (EBITDA).
